Investment Rating - The report assigns a "Buy" rating for the company, with a target price of HKD 48.24, based on a DCF valuation method [8][10]. Core Insights - The company focuses on the development of innovative drugs in the metabolic and oncology fields, with promising pipelines such as LAE102 and LAE002, which are expected to address significant market needs and have strong potential for business development [8][10]. - LAE102, targeting the ActRII pathway, shows superior muscle gain and fat loss potential compared to existing GLP-1 drugs, addressing the muscle loss issue associated with weight loss treatments [8][10]. - LAE002 is positioned as a leading AKT inhibitor, addressing drug resistance in advanced breast cancer, with a successful licensing agreement with Qilu Pharmaceutical, validating its pipeline value [8][10]. Summary by Sections 1. Company Overview - The company, established in 2016, focuses on developing therapies for metabolic diseases, cancer, and liver fibrosis, with a robust pipeline including LAE102, LAE103, and LAE002 [13][21]. 2. Metabolic Pipeline - The ActRII pipeline demonstrates differentiated mechanisms with superior safety and muscle gain effects, potentially becoming a cornerstone therapy in weight loss when combined with GLP-1 drugs [8][10]. - Clinical data shows LAE102's effectiveness in fat reduction and muscle preservation, outperforming other small nucleic acid drugs in terms of muscle gain [8][10]. 3. Oncology Pipeline - LAE002 effectively blocks the PI3K/AKT/mTOR signaling pathway, addressing drug resistance in HR+/HER2- breast cancer, and has secured a licensing deal with Qilu Pharmaceutical, enhancing its commercial prospects [8][10]. - The company is advancing LAE002 through multiple clinical trials, with promising results in terms of efficacy and safety compared to existing treatments [8][10]. 4. Financial Projections - Revenue projections for the company are estimated at HKD 730 million in 2026, with a significant increase in net profit expected in the same year [8][10].

Investment Rating - The report assigns a "Buy" rating for the company, with a target price of HKD 48.24, based on a DCF valuation method [8][10]. Core Insights - The company focuses on the development of innovative therapies in the fields of metabolism, oncology, and liver fibrosis, with a strong emphasis on its core pipelines LAE102 and LAE002 [13][21]. - The ActRII pipeline is differentiated in its mechanism, showing superior safety and muscle gain effects, which could position it as a cornerstone therapy in weight loss when combined with GLP-1 drugs [8][26]. - The LAE002 pipeline addresses the issue of drug resistance in advanced breast cancer, with a successful licensing agreement with Qilu Pharmaceutical, validating its pipeline value [8][67]. Summary by Sections 1. Company Overview - The company was established in 2016 and went public on June 29, 2023, on the Hong Kong Stock Exchange, focusing on innovative therapies for metabolic diseases, cancer, and liver fibrosis [13][21]. 2. Metabolism Pipeline - The ActRII pipeline has shown promising results in muscle gain and fat loss, with LAE102 demonstrating significant improvements over existing treatments [8][36]. - Clinical data indicates that LAE102 can effectively reduce fat while preserving muscle mass, outperforming other small nucleic acid drugs in terms of muscle gain [57][58]. 3. Oncology Pipeline - LAE002 is a potent pan-AKT inhibitor that addresses drug resistance in advanced breast cancer, with a focus on HR+/HER2- subtypes, showing comparable efficacy to existing treatments but with better safety profiles [67][68]. - The company has completed patient enrollment for the Phase III clinical trial of LAE002, marking a significant milestone towards potential market entry [71]. 4. Financial Projections - Revenue projections for the company are expected to reach HKD 730 million in 2026, with a net profit forecast of HKD 400 million [1][8]. - The company anticipates significant growth in revenue, with a projected increase of 584.04% year-on-year in 2026 [1]. 5. Research and Development - The company has consistently increased its R&D spending, with projections of HKD 2.5 billion in 2025, reflecting its commitment to innovation and pipeline development [24][25].

Summary of Key Points from the Conference Call Records Industry Overview - **Pharmaceutical Industry**: The innovative drug sector is experiencing a recovery with a clean chip structure, driven by upcoming academic conferences (AACR, ASCO) in Q2 2026, which are expected to boost market sentiment. Key companies include Innovent Biologics and Baillie Gifford [1][2]. - **Medical Devices**: The inventory destocking phase is nearly complete, with performance expected to improve in 2026 due to equipment renewal policies and the resumption of procurement processes. Notable companies include Aohua Endoscopy and Mindray Medical [1][5]. - **Traditional Chinese Medicine (TCM)**: Valuations are at historical lows, with growth expected from the new essential drug catalog and the implementation of the "986" policy. The recovery of in-hospital products is anticipated to outpace OTC products [1][10]. - **Active Pharmaceutical Ingredients (APIs)**: The antibiotic supply chain is seeing price increases driven by Indian import policies. Fluoroquinolone is at a loss margin but has strong price increase expectations [1][11]. Core Insights and Arguments - **Innovative Drug Sector**: The rebound is attributed to strong industry fundamentals, improved cash flow, and a growing number of companies turning profitable. The focus is on leading biopharma companies benefiting from ETF investments, such as Innovent Biologics and Baillie Gifford [2][3]. - **LaiKai Pharmaceuticals**: Recommended due to its significant efficacy in muscle gain and fat loss compared to small nucleic acid drugs. The upcoming Phase III clinical trial results for LAE002 in breast cancer are expected to be revealed in Q2 2026 [3][4]. - **CRO Sector**: Expected to maintain steady growth, with Kanglong Chemical's small molecule CDMO business projected to grow by 15%-20% in 2026, benefiting from the approval of its first API in the U.S. and several NDA milestones [1][13]. Additional Important Content - **Medical Device Sector**: The recovery is supported by three main drivers: improved terminal demand, ongoing equipment renewal policies, and normalized procurement processes starting in 2025 [5][6]. - **High-Value Consumables**: The sector is expected to see growth driven by innovation and overseas expansion, with a focus on companies like Spring Medical [7][8]. - **Low-Value Consumables and IVD**: Companies are accelerating overseas expansion due to tariff impacts, with many establishing overseas factories. The IVD sector is expected to rebound in 2026 as pricing pressures ease [8][9]. - **Investment Opportunities in TCM**: Companies like Yunnan Baiyao and East China Pharmaceutical are highlighted for their strong cash flow and high dividend rates, making them attractive during risk-averse market conditions [10][11]. - **Market Dynamics for APIs**: The antibiotic sector is experiencing price increases due to protective policies in India, while the market for sartans is stabilizing with potential for price increases as competition decreases [11][12]. Performance Expectations for 2026 - **Medical Services**: Expected revenue growth for major companies like Aier Eye Hospital and Tongce Medical is projected between 0%-10% [19]. - **CRO Sector**: Revenue growth for Kanglong Chemical and Kelaiying is expected to be in the range of 10%-15% [19]. - **API Sector**: Companies like Puluo Pharmaceutical and Tianyu Co. are expected to see revenue growth between 0%-10% and 10%-30%, respectively [19][20]. - **Innovative Drugs and Formulations**: Companies like Betta Pharmaceuticals and Enhua Pharmaceuticals are projected to have varied growth rates, with some facing challenges due to pricing pressures [20]. This summary encapsulates the key insights and projections from the conference call records, providing a comprehensive overview of the pharmaceutical and medical device industries, along with specific company highlights and market dynamics.

Investment Rating - The report maintains an "Accumulate" rating for the industry [7] Core Insights - The medical and biological sector has experienced a decline of 2.77% from March 16 to March 22, ranking 8th out of 31 sectors, and a year-to-date decline of 2.90%, ranking 20th out of 31 sectors [1][11] - The disposable glove sector is entering a price increase window due to rising costs driven by raw material prices, particularly for nitrile gloves, which are influenced by international oil prices and basic chemical prices [2][12] Industry Dynamics - The primary raw materials for disposable gloves are sourced from the petrochemical system, with costs closely tied to international oil prices. Recent increases in the prices of butadiene (up 19.6%) and acrylonitrile (up 10.3%) have significantly raised the cost of nitrile latex, which saw a price increase of approximately 16.7% in the North China market [2][12][12] Company Dynamics - **Xinnoway**: Achieved revenue of 2.158 billion yuan in 2025, a year-on-year increase of 8.93%. The biopharmaceutical segment saw a revenue increase of 192.65% [3][13] - **Deqi Pharmaceuticals**: Reported revenue of 105 million yuan in 2025, a 14.5% increase. The company has made progress in its core products and secured a global exclusive licensing agreement for ATG-201, receiving an upfront payment of 80 million USD [4][14] - **Laikai Pharmaceuticals**: Generated revenue of 107 million yuan in 2025, primarily from the licensing of LAE002. The company is advancing its obesity and oncology pipelines [5][15] - **China Resources Sanjiu**: Achieved revenue of 31.603 billion yuan in 2025, a 14.43% increase, and net profit of 3.421 billion yuan, a 1.58% increase. The company completed the acquisition of a 28% stake in Tian Shi Li, enhancing its business structure [6][17] Suggested Focus Areas - The report suggests paying attention to the innovative drug industry chain [5][18]

Investment Rating - The report maintains an "Increase" rating for the pharmaceutical and biotechnology sector [5]. Core Insights - The pharmaceutical and biotechnology sector experienced a slight decline of 0.22% this week, ranking 13th out of 31 sectors, and a year-to-date decline of 0.13%, ranking 23rd out of 31 sectors [8]. - A significant milestone was achieved with the approval of the first invasive brain-computer interface medical device by the National Medical Products Administration, marking a transition from technical exploration to clinical application [9]. - The launch of a national major science and technology project for innovative drugs targeting Alzheimer's disease indicates a strong governmental focus on drug development for critical diseases in the central nervous system [10]. Summary by Sections 1. Market Observation - The pharmaceutical and biotechnology sector has seen a decline of 0.22% this week and 0.13% year-to-date, indicating a market correction [8]. 2. Industry Dynamics 2.1 Brain-Computer Interface Milestone - The approval of the brain-computer interface system by the National Medical Products Administration represents the first global launch of an invasive medical device, aimed at assisting patients with cervical spinal cord injuries [9]. 2.2 Alzheimer's Disease Drug Development - The initiation of a national project for innovative Alzheimer's drugs highlights the importance of addressing urgent clinical needs in the central nervous system, potentially leading to technological breakthroughs and industrial advancements [10]. 3. Company Dynamics 3.1 Kanglong Chemical - Kanglong Chemical announced a strategic partnership with Eli Lilly for the commercialization of the oral GLP-1 drug Orforglipron, receiving a $200 million investment to enhance its technical capabilities [11]. 3.2 Laika Pharmaceutical - Laika Pharmaceutical successfully completed Phase I SAD studies for LAE102 in the U.S. and is planning Phase II trials, indicating accelerated global development [12]. 3.3 Hotgen Biotech - Hotgen Biotech's innovative drug SGC001 has completed its first administration in Phase II clinical trials for heart attack treatment, marking significant progress in its development [13]. 3.4 East China Pharmaceutical - East China Pharmaceutical's HDM2024 has received FDA approval for Phase I clinical trials, targeting advanced solid tumors, enhancing its competitive position in oncology [14]. 3.5 Kelun Pharmaceutical - Kelun Pharmaceutical's SKB575 has been approved for clinical trials targeting atopic dermatitis, showcasing its potential as a best-in-class treatment with a long dosing interval [15]. 4. Areas of Focus - The report suggests focusing on the innovative drug supply chain and the brain-computer interface sector for potential investment opportunities [16].

Investment Rating - The report maintains an "Increase" rating for the pharmaceutical and biotechnology sector [5]. Core Insights - The pharmaceutical and biotechnology sector experienced a slight decline of 0.22% this week, ranking 13th out of 31 sectors, and a year-to-date decline of 0.13%, ranking 23rd out of 31 sectors [8]. - A significant milestone was achieved with the approval of the first invasive brain-computer interface medical device by the National Medical Products Administration, marking a transition from technical exploration to clinical application, which opens commercial opportunities in the field of neuroregulation and implantable medical devices [9]. - The launch of a national major scientific research project for innovative drugs targeting Alzheimer's disease indicates the government's commitment to addressing urgent clinical needs in the central nervous system, potentially accelerating technological breakthroughs and industrialization in this area [10]. Company Dynamics - Kanglong Chemical announced a strategic partnership with Eli Lilly for the commercialization of the oral GLP-1 drug Orforglipron, receiving a $200 million investment to enhance its technical capabilities [11]. - Laika Pharmaceuticals successfully completed Phase I SAD studies for LAE102 in the U.S. and is planning Phase II trials, indicating progress in global development [12]. - Hotgen Biotech's innovative drug SGC001 has completed its first administration in Phase II clinical trials for treating acute myocardial infarction, marking a significant advancement in this therapeutic area [13]. - East China Pharmaceutical's self-developed dual-target ADC drug HDM2024 has received FDA approval for Phase I clinical trials in the U.S., enhancing its competitiveness in the oncology field [14]. - Kelun Biotech's SKB575 has been approved for clinical trials targeting atopic dermatitis, showcasing its potential as a best-in-class treatment with a long dosing interval [15]. Suggested Focus Areas - The report suggests focusing on the innovative drug supply chain and the brain-computer interface sector for potential investment opportunities [16].

Core Insights - The article highlights the significant breakthrough of LAE102, a drug developed by the company, in the competitive global metabolism and weight loss market, showcasing its potential to attract attention from both capital markets and clinical fields [4] Group 1: Drug Performance - LAE102 demonstrated remarkable results in a Phase I single-dose escalation study in the U.S., showing significant muscle gain and fat loss effects in healthy postmenopausal women after 4 weeks of treatment, with a 5.06% increase in lean body mass and a 0.12% decrease in fat mass compared to a placebo group [4] - Compared to competitors, LAE102 outperformed Bimagrumab in muscle gain within 4-5 weeks, while also showing strong fat loss effects, indicating its superior efficacy in the "muscle gain and fat loss" arena [5] Group 2: Safety and Development - The safety profile of LAE102 is impressive, with no serious adverse events reported, aligning closely with previous Phase I trial results in China, which enhances its potential as a leading drug in the muscle gain and fat loss sector [5] - The company is accelerating the development of LAE102 and actively engaging with potential partners to expedite global commercialization, positioning it as a highly sought-after project among major pharmaceutical companies in the future [6]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Laekna, Inc. 來凱醫藥有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2105） 療效方面，美國SAD研究顯示：單次給藥後，受試者身體組成部分呈現令人鼓舞 的改善趨勢，觀察到與劑量相關的增肌減脂效果。LAE102單次給藥後的第29天， 最高暴露量的組別其平均瘦體重較基線增加5.06 %（ 安慰劑組較基線減少1.34 % ）， 平均 脂肪 量較 基線 減少0.12 %（ 安 慰劑 組較 基線 增加2.11 % ）。 單次給 藥LAE102 導 致啟動素A水準顯著且持續地上升，顯示出強有力的靶點結合。靶點結合的持續 時間與劑量水準相關。本集團計劃在即將召開的科學會議上公佈詳細研究結果。 – 1 – 上述積極結果進一步支持LAE102作為心血管代謝疾病治療的創新療法。本集團正 積 極 規 劃 II 期 臨 床 試 驗 ， 以 ...

Group 1 - The core point of the article is that Laekna Therapeutics has initiated a Phase I multi-dose expansion study for LAE102, aimed at treating obesity in China, and has completed the dosing of the first subject [1] Group 2 - The study is part of the company's efforts to advance its pipeline in the obesity treatment sector [1] - The announcement was made on December 22, indicating the company's ongoing commitment to research and development in the pharmaceutical industry [1] - The initiation of this study may present potential investment opportunities in the healthcare sector, particularly in obesity treatments [1]

Core Viewpoint - The company, 来凯医药-B (02105), has initiated a Phase I multi-dose expansion study for LAE102, aimed at treating obesity, with the first subject having been dosed [1] Group 1: Study Details - The Phase I multi-dose expansion study is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of LAE102 in 60 overweight/obese subjects [1] - Subjects will be randomly assigned to either the LAE102 group or the placebo group, receiving treatment for a duration of 6 months [1] - The study is based on previously observed positive one-month treatment results from an earlier MAD study, aiming to further assess the efficacy and safety characteristics after prolonged treatment [1] Group 2: Company Commitment - The company is dedicated to providing precision treatment options for patients suffering from obesity or metabolic diseases who require new therapeutic alternatives [1]